AMLX vs LQDA
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
AMLX · Amylyx Pharmaceuticals$26.02 ▼ 0.69%
LQDA · Liquidia$54.43 ▼ 3.88%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- AMLX +75.6%
- LQDA +82.2%
Head to head
| Metric | AMLX | LQDA |
|---|---|---|
| Price | $26.02 | $54.43 |
| Change today | ▼ 0.69% | ▼ 3.88% |
| Market cap | $3.35B | $4.90B |
| Return, 3 months | -31.8% | -22.5% |
| Return, year to date | +115.4% | +57.8% |
| Return, 1 year | +77.4% | +87.0% |
| P/E (TTM) | – | – |
| P/B | 4.4 | -193.0 |
| P/E percentile vs own 5y | 3rd | 0th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | +314.6% |
| Net profit growth (YoY) | -32.3% | -6,589.2% |
| Gross margin | – | 92.7% |
| Operating margin | – | 47.1% |
| Net margin | – | -15.1% |
| Return on equity | -30.1% | – |
| Analyst target vs. price | +77.7% | +16.2% |
| Analyst buy share | 100% | 75% |
| RSI (14) | 39 | 59 |
| 30-day volatility | 58.0% | 94.0% |
| Max drawdown, 1 year | -34.4% | -71.5% |
| Trend read | Leaning bearish | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- LQDA is the largest of the group by market value.
- LQDA has returned the most over the past year.
- AMLX has been the calmest stock over the last 30 days.